IBSRELA Sales Surge 73%: U.S. Biotech Patent Defense Until 2042

Ardelyx, Inc. (NASDAQ: ARDX) reported that its 2025 revenue for IBSRELA rose 73% year-over-year to $274.2 million, driving total 2025 revenue to $407.3 million (approximately KRW 360 billion and KRW 530 billion, respectively).

Looking ahead to 2026, the company projects IBSRELA sales of $410 million to $430 million and XPHOZAH sales of $110 million to $120 million, for combined revenue of roughly KRW 680 billion to KRW 720 billion. Ardelyx continues to operate at a net loss as it invests in growth.

On the R&D front, Ardelyx is conducting the ACCEL Phase 3 trial in patients with chronic idiopathic constipation and advancing preclinical development of its next-generation NHE3 inhibitor, RDX10531. The company also secured a new U.S. patent covering formulations of both IBSRELA and XPHOZAH, extending tenapanor formulation protection through 2042.

To bolster awareness among patients and healthcare professionals, Ardelyx announced the 2026 Derek Forfang Patient Advocate Award on March 12—recognizing advocacy for chronic kidney disease patients—and on March 9 highlighted the publication of a review and retrospective analysis on tenapanor’s speed of symptom relief in IBS-C patients.

Based in Waltham, Massachusetts, Ardelyx is a commercial-stage biopharma specializing in gastrointestinal and renal therapies, including IBSRELA for IBS-C and XPHOZAH for hyperphosphatemia in dialysis-dependent chronic kidney disease. Like many U.S. biotech and healthcare companies, Ardelyx employs a model of driving revenue growth through a focused portfolio of specialty products and pipeline programs, while sustaining short-term losses to fund research and commercial expansion.